title: [Influence of the Site of Port Insertion on the Flow Velocity of 5-FU Continuous Intravenous Injection by Using a Compression-Type Portable Continuous Infuser for Colorectal Cancer Patients].
abstract: For the continuous intravenous injection off luorouracil (5-FU) over 46 hours in a chemotherapeutic regimen for colorectal cancer, a compression-type portable continuous infuser is used. However, there is an error in the flow velocity. Errors in the dose or time of administration completion may influence the efficacy and safety of 5-FU. Therefore, it is necessary to reduce the error in the flow velocity. The type of diluent, air temperature, and concentration of 5-FU are reportedly factors influencing the flow velocity. However, no study has examined the influence of the site of port insertion. In this study, we investigated factors associated with the flow velocity of 5-FU continuously and intravenously injected by using an infuser in patients with colorectal cancer, among whom the site of port insertion differed. The results showed that the site of port insertion influenced the flow velocity during the continuous intravenous injection of 5-FU using an infuser. It is important to reduce the error in the flow velocity by considering the site of port insertion in addition to the concentration of 5-FU and the air temperature.
authors.affiliation: Dept. of Pharmacy, Osaka Medical College Hospital.
authors.forename: Chieko
authors.initials: C
authors.lastname: Maki
authors.forename: Emi
authors.initials: E
authors.lastname: Goto
authors.forename: Makoto
authors.initials: M
authors.lastname: Hosomi
authors.forename: Takeo
authors.initials: T
authors.lastname: Hata
authors.forename: Masami
authors.initials: M
authors.lastname: Nishihara
authors.forename: Masahiro
authors.initials: M
authors.lastname: Goto
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Yamamoto
authors.forename: Takahiro
authors.initials: T
authors.lastname: Katsumata
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D062666:Vascular Access Devices
chemical_list: D005472:Fluorouracil